论文部分内容阅读
本文报告ＨＤＭＴＸＣＦＲ治疗原发性骨肉瘤１８例的临床疗效，所有病例除一例经Ｘ线诊断外，余经病理学确诊。ＭＴＸ每疗程剂量０．５～３．０／Ｍ￣２，静滴ＭＴＸ开始至ＣＦ解救时间为１６～１８小时，其毒副反应轻，无一例发生意外。骨肉瘤术后辅助化疗后２年生存率５５．６％，生存５年以上者３例。本文提示，骨肉瘤的辅助化疗有肯定疗效，ＨＤＭＴＸ为有效的辅助化疗方案之一，但剂量不宜过低，只要注意水化，尿碱化及ＣＦ解救，此疗法是安全的。
This article reports the clinical efficacy of HDMTXCFR in the treatment of primary osteosarcoma in 18 cases. All cases except one case were diagnosed by X-ray and the rest were confirmed by pathology. The dosage of MTX is 0.5～3.0/M~2 per treatment. The time from MTX start to CF rescue of intravenous instillation is 16 to 18 hours. The toxic side reaction is mild, and there is no accident. The 2-year survival rate of osteosarcoma after adjuvant chemotherapy was 55.6%, and 3 cases survived more than 5 years. This article suggests that adjuvant chemotherapy for osteosarcoma has a positive effect. HDMTX is one of the effective adjuvant chemotherapy regimens, but the dose should not be too low. As long as attention is paid to hydration, urinary alkalization and CF rescue, this therapy is safe.